To assess the potential impact of KIR/HLA genotypes on relapse risk in patients receiving HDC/IL-2 immunotherapy, we determined the HLA and KIR genotypes in 81 AML patients in the Re:Mission trial. The gene discussed is KIR3DL1; the disease is acute myeloid leukemia.